These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 22074249)
1. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. Kopansky E; Shamay Y; David A J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249 [TBL] [Abstract][Full Text] [Related]
2. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells. David A; Kopecková P; Minko T; Rubinstein A; Kopecek J Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799 [TBL] [Abstract][Full Text] [Related]
3. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. Etrych T; Mrkvan T; Ríhová B; Ulbrich K J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976 [TBL] [Abstract][Full Text] [Related]
4. G3-C12 Peptide Reverses Galectin-3 from Foe to Friend for Active Targeting Cancer Treatment. Sun W; Li L; Yang Q; Shan W; Zhang Z; Huang Y Mol Pharm; 2015 Nov; 12(11):4124-36. PubMed ID: 26393405 [TBL] [Abstract][Full Text] [Related]
5. Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate. Fan M; Yang D; Liang X; Ao J; Li Z; Wang H; Shi B Biomed Pharmacother; 2015 Mar; 70():268-73. PubMed ID: 25776511 [TBL] [Abstract][Full Text] [Related]
6. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067 [TBL] [Abstract][Full Text] [Related]
7. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Song S; Liu D; Peng J; Sun Y; Li Z; Gu JR; Xu Y Int J Pharm; 2008 Nov; 363(1-2):155-61. PubMed ID: 18692120 [TBL] [Abstract][Full Text] [Related]
8. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893 [TBL] [Abstract][Full Text] [Related]
9. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy. Yang Y; Pan D; Luo K; Li L; Gu Z Biomaterials; 2013 Nov; 34(33):8430-43. PubMed ID: 23896006 [TBL] [Abstract][Full Text] [Related]
10. A novel α Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244 [TBL] [Abstract][Full Text] [Related]
11. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. Yang Y; Zhou Z; He S; Fan T; Jin Y; Zhu X; Chen C; Zhang ZR; Huang Y Biomaterials; 2012 Mar; 33(7):2260-71. PubMed ID: 22189143 [TBL] [Abstract][Full Text] [Related]
12. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer. Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367 [TBL] [Abstract][Full Text] [Related]
13. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin. Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206 [TBL] [Abstract][Full Text] [Related]
14. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307 [TBL] [Abstract][Full Text] [Related]
15. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences. Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618 [TBL] [Abstract][Full Text] [Related]
16. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705 [TBL] [Abstract][Full Text] [Related]
17. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery. Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555 [TBL] [Abstract][Full Text] [Related]
18. Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12. Sun W; Li L; Li LJ; Yang QQ; Zhang ZR; Huang Y Acta Pharmacol Sin; 2017 Jun; 38(6):806-822. PubMed ID: 28065935 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells. Kovar L; Etrych T; Kabesova M; Subr V; Vetvicka D; Hovorka O; Strohalm J; Sklenar J; Chytil P; Ulbrich K; Rihova B Tumour Biol; 2010 Aug; 31(4):233-42. PubMed ID: 20556593 [TBL] [Abstract][Full Text] [Related]
20. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. Pimm MV; Perkins AC; Strohalm J; Ulbrich K; Duncan R J Drug Target; 1996; 3(5):385-90. PubMed ID: 8866657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]